Maximum Strength Zantac is a Oral Tablet, Coated in the Human Otc Drug category. It is labeled and distributed by Boehringer Ingelheim Pharmaceuticals Inc.. The primary component is Ranitidine Hydrochloride.
| Product ID | 0597-0121_75260c56-23f1-66dd-10ba-4728a73e5bf9 |
| NDC | 0597-0121 |
| Product Type | Human Otc Drug |
| Proprietary Name | Maximum Strength Zantac |
| Generic Name | Ranitidine |
| Dosage Form | Tablet, Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2006-12-21 |
| Marketing Category | NDA / NDA |
| Application Number | NDA021698 |
| Labeler Name | Boehringer Ingelheim Pharmaceuticals Inc. |
| Substance Name | RANITIDINE HYDROCHLORIDE |
| Active Ingredient Strength | 150 mg/1 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2012-06-08 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Marketing Category | NDA |
| Application Number | NDA021698 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2006-12-21 |
| Marketing End Date | 2021-11-30 |
| Ingredient | Strength |
|---|---|
| RANITIDINE HYDROCHLORIDE | 150 mg/1 |
| SPL SET ID: | 4da36a98-7363-4a8a-9bfe-5dfa7d2e1268 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0597-0121 | Maximum Strength Zantac | ranitidine |
| 10202-852 | 7 Select Acid Reducer | Ranitidine |
| 0904-6350 | Acid Reducer | Ranitidine |
| 0113-7950 | basic care acid reducer | Ranitidine |
| 0113-7852 | basic care acid reducer 150 | Ranitidine |
| 0113-7876 | basic care acid reducer 75 | Ranitidine |
| 0113-0852 | Good Sense Acid Reducer | Ranitidine |
| 0113-0876 | Good Sense Acid Reducer | Ranitidine |
| 10202-712 | MAXIMUM STRENGTH RANITIDINE | Ranitidine |
| 0121-0727 | Ranitidine | RANITIDINE |
| 0121-4727 | Ranitidine | RANITIDINE |
| 0172-4357 | Ranitidine | Ranitidine |
| 0172-4358 | Ranitidine | Ranitidine |
| 0363-0352 | Ranitidine | Ranitidine |
| 0440-8300 | Ranitidine | Ranitidine |
| 0440-8305 | Ranitidine | Ranitidine |
| 0615-4513 | Ranitidine | Ranitidine |
| 0615-4514 | Ranitidine | Ranitidine |
| 0615-8021 | Ranitidine | Ranitidine |
| 0781-6087 | Ranitidine | Ranitidine |
| 0904-6349 | Ranitidine | Ranitidine |
| 0904-6716 | Ranitidine | Ranitidine |
| 0904-6921 | Ranitidine | Ranitidine |
| 10544-056 | Ranitidine | Ranitidine |
| 10544-438 | Ranitidine | Ranitidine |
| 10544-516 | Ranitidine | Ranitidine |
| 11673-849 | Ranitidine | Ranitidine |
| 0904-6715 | ranitidine 75 | Ranitidine |
| 11673-023 | up and up ranitidine | Ranitidine |
| 0363-0852 | wal zan 150 | Ranitidine |
| 0363-0950 | wal zan 150 | Ranitidine |
| 0363-1876 | wal zan 75 | Ranitidine |
| 0363-0362 | Wal-Zan | Ranitidine |
| 0597-0122 | Zantac 75 | ranitidine |
| 0597-0120 | Zantac Maximum Strength 150 Cool Mint | ranitidine |